$102 Million is the total value of Asymmetry Capital Management, L.P.'s 36 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OPTN | Sell | OPTINOSE INC | $9,396,000 | +38.5% | 335,826 | -0.9% | 9.24% | +8.8% |
| PTCT | Sell | PTC THERAPEUTICS | $6,916,000 | -20.0% | 205,031 | -35.8% | 6.80% | -37.1% |
| JAZZ | Sell | JAZZ PHARMACEUTICALS | $5,104,000 | +8.0% | 29,625 | -5.4% | 5.02% | -15.1% |
| CNC | Sell | CENTENE CORP | $4,812,000 | -6.7% | 39,058 | -19.1% | 4.73% | -26.7% |
| UNH | Sell | UNITEDHEALTH GROUP INC | $3,546,000 | -5.4% | 14,452 | -17.5% | 3.49% | -25.7% |
| AERI | Sell | AERIE PHARMACEUTICALS INC | $3,361,000 | -11.1% | 49,756 | -28.6% | 3.30% | -30.1% |
| DGX | Sell | QUEST DIAGNOSTICS | $2,702,000 | -16.4% | 24,575 | -23.7% | 2.66% | -34.3% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $2,644,000 | +6.9% | 26,910 | -9.8% | 2.60% | -16.0% |
| HRTX | Sell | HERON THERAPEUTICS | $2,583,000 | +21.0% | 66,488 | -14.0% | 2.54% | -4.9% |
| NTRA | Sell | NATERA INC | $2,237,000 | -25.9% | 118,869 | -63.5% | 2.20% | -41.7% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $2,064,000 | -29.5% | 132,160 | -32.1% | 2.03% | -44.6% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $1,487,000 | -31.1% | 11,249 | -61.4% | 1.46% | -45.8% |
| DRRX | Sell | DURECT CORPORATION | $1,074,000 | -33.3% | 688,446 | -8.5% | 1.06% | -47.6% |
| MTEM | Exit | MOLECULAR TEMPLATES INC | $0 | – | -1,700 | -100.0% | -0.02% | – |
| TVTY | Exit | TIVITY HEALTH INC | $0 | – | -24,601 | -100.0% | -1.22% | – |
| NVRO | Exit | NEVRO CORP | $0 | – | -13,087 | -100.0% | -1.42% | – |
| PEN | Exit | PENUMBRA INC | $0 | – | -10,279 | -100.0% | -1.49% | – |
| PBYI | Exit | PUMA BIOTECHNOLOGYINC | $0 | – | -18,057 | -100.0% | -1.54% | – |
| ARRY | Exit | ARRAY BIOPHARMA INC | $0 | – | -81,649 | -100.0% | -1.67% | – |
| TCMD | Exit | TACTILE SYSTEMS TECHNOLOGY INC | $0 | – | -42,460 | -100.0% | -1.69% | – |
| INGN | Exit | INOGEN INC | $0 | – | -12,471 | -100.0% | -1.92% | – |
| LJPC | Exit | LA JOLLA PHARMACEUTICAL CO | $0 | – | -55,864 | -100.0% | -2.08% | – |
| BSX | Exit | BOSTON SCIENTIFIC CORP | $0 | – | -68,270 | -100.0% | -2.33% | – |
| PFE | Exit | PFIZER INC | $0 | – | -53,242 | -100.0% | -2.36% | – |
| SNDX | Exit | SYNDAX PHARMACEUTICALS INC | $0 | – | -135,974 | -100.0% | -2.42% | – |
| KALA | Exit | KALA PHARMACEUTICALS | $0 | – | -134,250 | -100.0% | -2.66% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-07
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.